Abstract
Purpose: Clinical trials provide evidence that dose-dense chemotherapy (ddC) is more efficacious than standard chemotherapy schedules in the treatment of early breast cancer (EBC). The impact on toxicity and healthcare utilisation remains uncertain in real-world populations. The aim of this retrospective adjusted cohort comparison was to measure the impact following adoption of ddC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.